Telix and Monrol Expand Alliance to Include Lutetium Supply
Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR…
Read moreNews & Views
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Telix has been granted HREC approval and received CTN clearance by the TGA to commence a Phase III study of the Company’s prostate cancer therapy candidate TLX591, in patients with advanced…
Read more
Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region
Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial…
Read more
Telix Pharmaceuticals Appoints Richard Valeix as EMEA President
News,
Telix announces Richard Valeix has joined the Telix executive leadership team in the role of President, Europe, Middle East and Africa…
Read more
Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement
Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development…
Read more
Japanese Renal Cancer Imaging Trial Meets Study Objectives
Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging product demonstrates safety and tolerability in Japanese…
Read more
Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent
Telix announces the launch of the international NOBLE Registry of Telix’s ‘rest of world’ prostate cancer imaging agent and the dosing of the first…
Read more
Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process
Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced the priority evaluation…
Read more
Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021
Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12 May…
Read more
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
Telix announces it has completed an agreement with Grand River Aseptic Manufacturing to perform GMP manufacturing of Telix’s prostate cancer imaging…
Read more